We have evaluated the efficacy of administering recombinant human erythropoietin (rh-Epo) to 11 healthy bone marrow donors weighing less than 30 kg. Three weeks before harvesting, the donors received 100 units/kg/day rh-Epo subcutaneously and oral iron supplementation (2.5 mg/kg twice daily). Six children with hematocrit values below the normal ranges for their ages after bone marrow harvesting received 150 units/kg rh-Epo three times a week for 2 weeks and oral iron supplementation at the same dose. No rh-Epo sideeffects were observed. Hematocrit values before harvesting increased to between 5.7 and 18.5 (mean 10.6 ± 1.2) above the baseline values (P = 0.0001). Hematocrit after harvesting decreased to between 4 and 19.5% (mean, 11.1) below the day 0 pre-harvest values. On day +15 all but one patient had a hematocrit value уbaseline value. No patient required transfusion during or after bone marrow harvest. Our results show that rh-Epo administration can avoid transfusion and has no side-effects in low weight child bone marrow donors.
Blood transfusions can cause unfavorable side-effects, principally allosensitization and infections. To avoid these risks in healthy bone marrow donors, it is common practice to remove a unit of the donor's own blood 1 or 2 weeks before bone marrow harvest. The blood is stored and used for autotransfusion if required by the donor during or immediately after bone marrow harvest. 1 In child donors this is difficult to perform due to problems of low blood volume. Therefore many of these donors have to receive allogeneic blood transfusion from anonymous donors or from a member of their family. 2 The present study was conducted to evaluate the efficacy and safety of human recombinant erythropoietin (rh-Epo) administration in 11 healthy bone marrow child donors weighing less than 30 kg in order to avoid allogeneic blood transfusions. 
Patients and methods
From May 1994 to July 1996, 11 healthy children (six boys and five girls) weighing less than 30 kg were entered into the protocol for low-weight bone marrow donors. The donors were HLA-identical with their sibling recipients. Their baseline hematocrit, reticulocyte count, 3 iron metabolism (serum iron, TIBC, transferrin, serum ferritin) and serum erythropoietin were normal for children of their age. Liver and renal functions and arterial blood pressure were also normal. None had thalassemia traits or had previously suffered convulsions. Parents' informed consent for marrow harvest and for the use of rh-Epo was obtained in all the cases. Donor characteristics are shown in Table 1 .
The donors received rh-Epo (Janssen-Cilag, Schaffhausen, Sweden) 100 units/kg/day subcutaneously on an outpatient basis for 3 weeks prior to marrow harvesting with oral iron gluconate 2.5 mg/kg twice daily. rh-Epo was administered by the parents after receiving instruction. The children were controlled for possible side-effects (bone, muscle and joint pain, fever, headache and pain at the site of the injection). Blood pressure was taken once a week.
On day 0 the hematocrit, reticulocyte and serum erythropoietin (immunoradiometry) were determined before marrow harvesting. Bank blood was available in case transfusion was required during harvesting. On day +1, hematocrit values were determined again, and if values fell below the normal ranges for the donor ages, 150 ml/kg rhEpo three times a week with oral iron supplementation (2.5 mg/kg twice a day) were administered for 2 weeks to raise values as close as possible to baseline. The results are expressed as mean ± s.d. The paired ttest was used to compare the results obtained before and after rh-Epo administration. Table 2 shows the hematocrit values before rh-Epo administration, on days 0 and +1, as well as the values on day +15 of the six patients who required rh-Epo following bone marrow harvest. Hematocrit values before harvesting increased to between 5.7 and 18.5 (mean 10.6 ± 1.2) above the baseline values (P = 0.0001). Hematocrit after harvesting decreased to between 4 and 19.5% (mean, 11.1) below the day 0 pre-harvest values. Baseline serum erythropoietin ranged from 0.05 to 15 IU (median, 4). Serum erythropoietin on the day of donation ranged from 7.5 to 97 IU (median, 30). The white blood cell and neutrophil count of all the donors fell within the normal ranges for their ages. No rh-Epo-related side-effects were observed. No donor required transfusion during or after the procedure. Nucleated marrow cell dose infused to the recipient ranged from 1.09 to 3.79 × 10 8 /kg (median 2.11 × 10 8 /kg). All the patients completed three weeks of treatment. Five of them required no further dose, since their hematocrit values on day +1 were у the normal values that are normal for their ages. 3 The six others received 2 further weeks of treatment of 150 ml/kg rh-Epo three times a week with oral iron supplementation (2.5 mg/kg/twice a day).
Results

Discussion
The results of the present study show the beneficial effects of rh-Epo administered to healthy low weight child bone marrow donors who are not amenable to autotransfusion.
None of our donors required heterologous blood transfusion following bone marrow harvest. These results are in agreement with those reported by York and co-workers 4 in a group of patients that included two children weighing less than 30 kg.
All children showed an excellent response to rh-Epo administration, with increments in hematocrit values of between 5.7 to 18.5%.
Five of the donors had normal or higher hematocrit values for their ages after marrow harvest and therefore did not require post-harvest rh-Epo. Although side-effects (bone, muscle, and joint pain, fever and headache) have been described after intravenous rh-Epo administration, we observed no side-effects with the subcutaneous route we utilize in our protocol.
There is an increasing use of peripheral blood stem cells following mobilization with growth factors in adult 5, 6 and pediatric 7 donors. Due to the low blood volume of donors less than 30 kg, priming the cell separator with heterologous blood is required. 7 Furthermore, although no adverse side-effects have been reported when growth factors are administered to healthy children, their long-term effects remain unknown. We therefore believe that bone marrow will continue to be the main source of stem cells in children less than 30 kg. In our experience, in these cases rh-Epo has been shown to cause no adverse side-effects and avoids heterologous blood transfusion.
